EL7.AI
Mergers & AcquisitionsMedium•18 November 2026•
4 min read

Aytu Shares Jump 46.2% to $2.66 After Rosemont Cash Offer

Key Facts

1Aytu shares closed at $2.66 on November 17, compared with $1.82 in the previous session.
2Rosemont is offering $2.70 per share in cash, equivalent to about $56 million on a fully diluted basis.
3The offer price represents a 51.7% premium to the November 13 close and a 41.1% premium to the 30-day volume-weighted average price.
4Aytu expects the deal to close by the end of 2026, subject to satisfaction or waiver of the tender offer conditions.

Aytu BioPharma shares jumped about 46.2% in the November 17 session, closing at $2.66, compared with the previous session’s close of $1.82, according to EL7 data. The move followed the company’s November 16 announcement of a definitive merger agreement under which Rosemont would acquire it through a cash tender offer priced at $2.70 per share. The offer equates to about $56 million on a fully diluted basis, according to the company’s fiscal first-quarter 2027 results. The deal does not constitute a completed acquisition; its closing depends on the satisfaction or waiver of the tender offer conditions. Aytu said completion of the offer is not subject to a financing condition.

Aytu said the offer price represents a 51.7% premium to the November 13 closing price and a 41.1% premium to the 30-day volume-weighted average price. The cash price gives shareholders a defined amount per share if the deal is completed under its terms. But the company’s shares closed at $2.66 on November 17, below the $2.70 offer price. The gap comes as the deal is still awaiting the start of the tender offer and satisfaction of its conditions. The company entered into the definitive agreement on November 16, before the session in which its shares recorded their sharp gain.

The deal consists of a tender offer followed by a second-step merger, and the offer requires tenders of shares representing at least a majority of Aytu’s outstanding shares, under the agreement’s terms. The company said its board unanimously approved the agreement and the transaction, deemed them fair and in the best interests of the company and its shareholders, and decided to recommend the offer. Some shareholders also agreed to tender their shares under support agreements, including entities affiliated with Nantahala Capital Management and Stonepine Capital Management. Those agreements do not waive the minimum tender condition. The deal remains subject to the other conditions set out in the merger agreement.

According to Aytu’s announcement, Rosemont intends to launch the tender offer and file a Schedule TO within 10 business days of the agreement announcement. The company said it will file a Schedule 14D-9 substantially concurrently with the launch of the offer. Aytu expects the deal to close by the end of calendar year 2026, subject to satisfaction or waiver of the offer conditions. This means the launch and procedures for the offer will precede the expected closing date. The agreement also provides for a potential termination fee of $2.4 million payable by Aytu to Rosemont in specified circumstances if the agreement is terminated.

The deal announcement coincided with Aytu’s results for the first quarter of its 2027 fiscal year, as net revenue rose 6.9% to $14.8 million from $13.9 million in the year-earlier period. At the same time, the company posted a net loss of $3.9 million, after reporting net income of $2.0 million in the first quarter of fiscal 2026. Cash and cash equivalents totaled $25.5 million on September 30, 2026, compared with $26.3 million on June 30. The company said revenue from its ADHD portfolio fell to $7.7 million from $13.2 million a year earlier. It attributed the decline mainly to reduced promotion as commercial resources shifted toward EXXUA, as well as competition from generic drugs.

By contrast, Aytu said EXXUA revenue reached $4.9 million in the fiscal first quarter, up 24.5% from $3.9 million in the fourth quarter of fiscal 2026. The product’s prescription count rose 32.5% quarter over quarter to 4,400 prescriptions. Revenue from the company’s pediatric portfolio also increased to $2.2 million from $0.7 million in the year-earlier period, which the company attributed mainly to an improved payer mix and lower returns. Rosemont described the deal as combining an established ADHD treatment portfolio and an emerging major depressive disorder asset with a U.S. commercial platform. Aytu said it will not hold a conference call to discuss the quarterly results because of the pending merger with Rosemont.

Open on chart